An interventional study of Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Disease, Metabolic, Diabetes Mellitus, Type 2 and Obesity and Obesity-related Medical Conditions, sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Bone Diseases, Metabolic with a site in Denmark — 2 open to participants now, 5 under way, none of them phase 3. Bone Diseases, Metabolic · Denmark.
Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 24th registered.
663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.
Browse Bone Diseases, Metabolic studies →2 of the 26 studies in Bone Diseases, Metabolic with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 60–75 · Women only · Healthy volunteers
Filip Krag Knop · Sites in Denmark
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 60 across 510 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 85 across the 23 interventional studies, 20 across the 3 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Esbjerg Hospital - University Hospital of Southern Denmark is the lead sponsor of 51 studies on the registry; 16 are open to participants now.
Esbjerg Hospital - University Hospital of Southern Denmark has 1 study filed under Bone Diseases, Metabolic — fewer than ten, so there is no comparison to draw.
3 of the studies in Bone Diseases, Metabolic with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06050577Odense University HospitalThe Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | 2027-01-15 |
| NCT07191353Odense University HospitalResistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women | 2027-03-01 |
| NCT07056322University of AarhusOptimal Meals to Reduce Bone Resorption in Women With Osteopenia | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glucose-dependent insulinotropic polypeptide (GIP) is released by the intestines in response to food intake and increases insulin secretion. Although short-term (\< 3 hours) stimulation with GIP decreases bone resorption in humans, the effect may vanish following continuous administration within 24 hours, at least in patients with type 1 diabetes. Whether the anti-resorptive effect of GIP can be maintained if the hormone is non-continuously administrated is unclear. As the first GIP receptor (GIPR) agonist, tirzepatide was recently approved for the treatment of obesity and type 2 diabetes in the USA and type 2 diabetes alone in the EU, there is a need to establish knowledge about the long-term effects of GIP on bone health, including if different exposure times to GIP have different skeletal effects.
This project will investigate whether GIP maintains its anti-resorptive potential if given as intermittent compared to continuous infusion in healthy men and women aged 18-40 years. Administration cycles involve intermittent (8 hours daily) and continuous (24 hours daily) injection of GIP for three days each. The effect of GIP will be measured by bone markers in blood samples, as well as in vitro activity and genetic alterations of bone cells (osteoclasts and osteoblasts) using bone marrow aspirates and bone marrow biopsies. Each participant will receive both administration cycles using a crossover design with a 14-28 days washout period between administrations of GIP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants that recive the intermittent administration first, followed by the continious
Other: Glucose-dependent Insulinotropic Polypeptide (GIP)
The participants that recives the continious administration first, follwoed by the intermittent
Other: Glucose-dependent Insulinotropic Polypeptide (GIP)
Recombinant human GIP (1-42)
Serum levels of CTX
Serum levels of CTX (bone resorption marker) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)
Time frame: During a three day period. With 14-28 days of washout between the two administration methods
Serum levels of osteocalcin and P1NP
Serum levels of osteocalcin and P1NP (bone formation markers) will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)
Time frame: During a three day period. With 14-28 days of washout between the two administration methods
Serum levels of GIP
Serum levels of GIP will be measured prior to, during, and at after the intervention, with both administration methods (continious and intermittent)
Time frame: During a three day period. With 14-28 days of washout between the two administration methods
Plan to share: No — individual participant data will not be shared following GDPR and local data mangament regulation. However data(anonymous) and results will be published once the study is completed.
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Sep 2026, 10 months.
Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 10 months is below that.
Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Nov 2026 → Sep 2026 and completion Nov 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esbjerg Hospital - University Hospital of Southern Denmark